About
Designing Tests That Predict Your Risk of Developing Cancer
Proteocyte is developing a platform of solutions to predict a patient’s risk of developing cancer. Our platform identifies specific protein biomarkers that operate in combination with proprietary algorithms, advanced imaging and digital pathology enabling us to predict an individuals’ probability of non-cancerous lesions progressing to invasive cancer.
Founded in 2011, Proteocyte identified the need to provide healthcare professionals with more objective and quantifiable information that would significantly improve the outcome for their patients.
Proteocyte’s first product, Straticyte™, is a test that predicts the progression of pre-malignant lesions to invasive oral cancer. Straticyte enables healthcare professionals to customize patient management/treatment, improving outcomes for patients at risk for developing oral cancer, while reassuring those patients who have minimal to no risk of disease progression.
Our Team
Steven Arless
Executive Chairman
Mark Hammar
Chief Executive Officer
Anthony Morlandt
Chief Medical Officer - USA
Barrie Renick
Chief Medical Officer - Canada
John Jordan
Chief Financial Officer
Ken Pritzker
Medical Director
David Mock
Medical Advisor
Jason Hwang
Principal Scientist & Lab Manager
Board of Directors
Steven Arless
Executive Chairman
Carlo Sistilli
Director
Anthony Morlandt
Director
Barrie Renick
Director
John Jordan
Director
Clinical Advisory Board
Eric Dierks
MD, DMD, FACS, FACD, FRCS(Ed)
Rui Fernandes
MD, DMD, FACS, FRCS
Deepak Kademani
MD, DMD, FACS
Diana Lin
MD
James Melville
DDS, FACS
Ian Witterick
MD, MSc, FRCSC
Simon Young
DDS, MD, PhD, FACS